Rui Wu1, Sixuan Guo2, Shuhui Lai3, Guixing Pan4, Linyi Zhang5, Huanbing Liu6. 1. The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. 2. The Second Clinical College, Medical College of Nanchang University, Nanchang, Jiangxi, China. 3. The First Clinical College, Medical College of Nanchang University, Nanchang, Jiangxi, China. 4. Shangrao Maternity and Child Care Hospital, Shangrao, Jiangxi, China. 5. School of Ophthalmology & Optometry, Nanchang University, Nanchang, Jiangxi, China. 6. The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China. liuhuanbing6911@sina.com.
Abstract
BACKGROUND: Gastric cancer (GC) is a primary reason for cancer death in the world. At present, GC has become a public health issue urgently to be solved to. Prediction of prognosis is critical to the development of clinical treatment regimens. This work aimed to construct the stable gene set for guiding GC diagnosis and treatment in clinic. METHODS: A public microarray dataset of TCGA providing clinical information was obtained. Dimensionality reduction was carried out by selection operator regression on the stable prognostic genes discovered through the bootstrap approach as well as survival analysis. FINDINGS: A total of 2 prognostic models were built, respectively designated as stable gene risk scores of OS (SGRS-OS) and stable gene risk scores of PFI (SGRS-PFI) consisting of 18 and 21 genes. The SGRS set potently predicted the overall survival (OS) along with progression-free interval (PFI) by means of univariate as well as multivariate analysis, using the specific risk scores formula. Relative to the TNM classification system, the SGRS set exhibited apparently higher predicting ability. Moreover, it was suggested that, patients who had increased SGRS were associated with poor chemotherapeutic outcomes. INTERPRETATION: The SGRS set constructed in this study potentially serves as the efficient approach for predicting GC patient survival and guiding their treatment.
BACKGROUND:Gastric cancer (GC) is a primary reason for cancer death in the world. At present, GC has become a public health issue urgently to be solved to. Prediction of prognosis is critical to the development of clinical treatment regimens. This work aimed to construct the stable gene set for guiding GC diagnosis and treatment in clinic. METHODS: A public microarray dataset of TCGA providing clinical information was obtained. Dimensionality reduction was carried out by selection operator regression on the stable prognostic genes discovered through the bootstrap approach as well as survival analysis. FINDINGS: A total of 2 prognostic models were built, respectively designated as stable gene risk scores of OS (SGRS-OS) and stable gene risk scores of PFI (SGRS-PFI) consisting of 18 and 21 genes. The SGRS set potently predicted the overall survival (OS) along with progression-free interval (PFI) by means of univariate as well as multivariate analysis, using the specific risk scores formula. Relative to the TNM classification system, the SGRS set exhibited apparently higher predicting ability. Moreover, it was suggested that, patients who had increased SGRS were associated with poor chemotherapeutic outcomes. INTERPRETATION: The SGRS set constructed in this study potentially serves as the efficient approach for predicting GC patient survival and guiding their treatment.
Entities:
Keywords:
Gastric cancer; Immune infiltration; Molecular typing; Prediction of efficacy of chemotherapy; Prognosis
Authors: Mathias Uhlen; Per Oksvold; Linn Fagerberg; Emma Lundberg; Kalle Jonasson; Mattias Forsberg; Martin Zwahlen; Caroline Kampf; Kenneth Wester; Sophia Hober; Henrik Wernerus; Lisa Björling; Fredrik Ponten Journal: Nat Biotechnol Date: 2010-12 Impact factor: 54.908
Authors: Sun Young Kim; Min Joo Yoon; Young Iee Park; Mi Jung Kim; Byung-Ho Nam; Sook Ryun Park Journal: Gastric Cancer Date: 2017-08-21 Impact factor: 7.370
Authors: Anna D Wagner; Wilfried Grothe; Johannes Haerting; Gerhard Kleber; Axel Grothey; Wolfgang E Fleig Journal: J Clin Oncol Date: 2006-06-20 Impact factor: 44.544
Authors: Florent Petitprez; Yann A Vano; Etienne Becht; Nicolas A Giraldo; Aurélien de Reyniès; Catherine Sautès-Fridman; Wolf H Fridman Journal: Cancer Immunol Immunother Date: 2017-09-07 Impact factor: 6.968